Clinical and economic impact of molecular testing for BRAF fusion in pediatric low-grade Glioma
Abstract Background Treatment personalization via tumor molecular testing holds promise for improving outcomes for patients with pediatric low-grade glioma (PLGG). We evaluate the health economic impact of employing tumor molecular testing to guide treatment for patients diagnosed with PLGG, particu...
Saved in:
Main Authors: | Juan David Rios (Author), Russanthy Velummailum (Author), Julie Bennett (Author), Liana Nobre (Author), Derek S. Tsang (Author), Eric Bouffet (Author), Cynthia Hawkins (Author), Uri Tabori (Author), Avram Denburg (Author), Petros Pechlivanoglou (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2022-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Early molecular diagnosis of BRAF status drives the neurosurgical management in BRAF V600E-mutant pediatric low-grade gliomas: a case report
by: Gianluca Piccolo, et al.
Published: (2022) -
Genomics in pediatric high-grade gliomas: Hope or hype: Practical implications for resource-limited settings
by: Anirban Das, et al.
Published: (2023) -
Optic pathway and hypothalamic glioma, old problems, new paradigms
by: Inci Yaman Bajin, et al.
Published: (2023) -
A novel GIT2-BRAF fusion in pilocytic astrocytoma
by: Jeffrey Helgager, et al.
Published: (2017) -
Adult high-grade malignant gliomas
by: Fable Zustovich, et al.
Published: (2011)